{"filing":{"accession_number":"0001213900-26-070415","cik":"0001839140","ticker":"RVRC","company_name":"Revium Rx.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"ea0295431-8k_revium.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1839140/000121390026070415/ea0295431-8k_revium.htm"},"events":[{"id":12673,"run_id":11243,"accession_number":"0001213900-26-070415","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Ms. Inna Martin resigned from her positions as Director, Chief Operating Officer, and President of Revium Rx, effective immediately on June 16, 2026. The filing centers on her departure from multiple senior leadership roles, with the separation agreement detailing the terms of her exit, including extended stock option exercise periods and sale restrictions. This is a material executive departure affecting the company's leadership structure.","company_name":"Revium Rx.","ticker":"RVRC","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9592,"accession_number":"0001213900-26-070415","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Ms. Inna Martin resigned from her positions as Director, Chief Operating Officer, and President of Revium Rx, effective immediately on June 16, 2026. The filing centers on her departure from multiple senior leadership roles, with the separation agreement detailing the terms of her exit, including extended stock option exercise periods and sale restrictions. This is a material executive departure affecting the company's leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T15:32:25.262297+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9592,"accession_number":"0001213900-26-070415","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Ms. Inna Martin resigned from her positions as Director, Chief Operating Officer, and President of Revium Rx, effective immediately on June 16, 2026. The filing centers on her departure from multiple senior leadership roles, with the separation agreement detailing the terms of her exit, including extended stock option exercise periods and sale restrictions. This is a material executive departure affecting the company's leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T15:32:25.262297+00:00","company_name":"Revium Rx.","ticker":"RVRC","filing_date":"2026-06-22"}]}